August 1, 2013

Gentiva® Health Services Reports Second Quarter 2013 Results

ATLANTA, Aug. 1, 2013 /PRNewswire/ -- Gentiva Health Services, Inc. (NASDAQ: GTIV), the largest provider of home health and hospice services in the United States based on revenue, today reported second quarter 2013 results.  Quarterly highlights include:

  • Net revenues of $414.4 million.
  • Adjusted income attributable to Gentiva shareholders per diluted share of $0.22.
  • Adjusted EBITDA of $39.0 million.
  • Free cash flow of $25.9 million.

Second quarter 2013 financial highlights include: 

  • Net revenues of $414.4 million, a decrease of 3% compared to $427.7 million for the quarter ended June 30, 2012.  During the quarter ended June 30, 2013, net revenues were negatively impacted by the 2013 home health Medicare rate reduction, the full-quarter effect of the 2% sequestration rate cut on our Medicare-based revenues and the sale or closure of branches in the prior year. Excluding the impact of branches sold or closed, net revenues would have been down 2% compared to the second quarter of 2012.  Net revenues included home health episodic revenues of $206.7 million, flat compared to $207.5 million in the 2012 second quarter.  Hospice revenues were $179.2 million, a decrease of 7% compared to $192.0 million in the 2012 second quarter.  Hospice represented 43% of total net revenues in the second quarter of 2013, compared to 45% in the 2012 second quarter.
  • Income attributable to Gentiva shareholders of $6.3 million, or $0.20 per diluted share, compared to $13.9 million, or $0.46 per diluted share, for the second quarter of 2012.
  • Adjusted income attributable to Gentiva shareholders of $6.8 million, compared with $10.7 million in the comparable 2012 period. On a diluted per share basis, adjusted income attributable to Gentiva shareholders was $0.22 for the second quarter of 2013 as compared to $0.35 for the second quarter of 2012.
  • Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) was $39.0 million in the second quarter of 2013 as compared to $48.3 million in the second quarter of 2012.  Adjusted EBITDA as a percentage of net revenues was 9.4% in the second quarter of 2013 versus 11.3% in the prior year period.

Adjusted income attributable to Gentiva shareholders and Adjusted EBITDA exclude charges related to restructuring, legal settlements, acquisition and integration activities and other special items.

Highlights for the six months ended June 30, 2013 include: 

  • Net revenues of $830.0 million, a decrease of 4% as compared to $863.3 million for the prior year period. Net revenues included home health episodic revenues of $414.1 million, compared to $418.1 million in the comparable 2012 period.  Hospice revenues were $358.7 million, compared to $387.7 million in the comparable 2012 period. 
  • Loss attributable to Gentiva shareholders of $200.8 million, or $6.51 per diluted share.  Income attributable to Gentiva shareholders in the comparable 2012 period was $18.7 million, or $0.61 per diluted share.
  • Adjusted income attributable to Gentiva shareholders of $13.9 million, compared with $18.1 million in the 2012 period. On a diluted per share basis, adjusted income attributable to Gentiva shareholders was $0.45 as compared with $0.59 in the corresponding period of 2012, prior to the $0.03 add-back in the first quarter of 2012 for credit agreement amendment expenses.
  • Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA) was $78.1 million as compared to $90.2 million in the 2012 period.  Adjusted EBITDA as a percentage of net revenues was 9.4% versus 10.5% in the prior-year period.  

Cash Flow and Balance Sheet Highlights

At June 30, 2013, the Company reported cash and cash equivalents of $185.1 million, up from $159.6 million at March 31, 2013.  Total outstanding debt was $910.2 million as of June 30, 2013.    Total Company days sales outstanding, or DSO, was 52 days at June 30, 2013, flat with the DSO at March 31, 2013.

For the second quarter of 2013, net cash provided by operating activities was $30.7 million, compared to $83.8 million in the prior year period for 2012, which included a significant benefit from the reduction of  DSO.  Free cash flow was $25.9 million for the second quarter of 2013, compared to $80.7 million in the prior year period.  Free cash flow is calculated as net cash provided by operating activities less capital expenditures.

Full-Year 2013 Outlook

Based on first half 2013 results and the potential fourth quarter 2013 impact of the proposed 2014 Medicare home health and hospice reimbursement rules, the Company now expects full-year net revenues to be in the range of $1.67 billion to $1.70 billion.  The Company continues to expect 2013 adjusted income attributable to Gentiva shareholders to be in the range of $0.90 to $1.10 on a diluted per share basis.

Non-GAAP Financial Measures

The information provided in this press release includes certain non-GAAP financial measures as defined under SEC rules. In accordance with SEC rules, the Company has provided, in the supplemental information and the footnotes to the tables, a reconciliation of those historical measures to the most directly comparable GAAP measures.

A reconciliation of adjusted income attributable to Gentiva shareholders to net income, the most directly comparable GAAP measure, is not accessible on a forward-looking basis without unreasonable effort due to the inherent difficulties in predicting the costs of restructuring, legal settlements and merger and acquisition activities and the impact of any future acquisitions or divestitures, which can fluctuate significantly and may have a significant impact on net income.

Conference Call and Webcast Details

The Company will comment further on its second quarter 2013 results during its conference call and live webcast to be held Thursday, August 1, 2013 at 9:00 a.m. Eastern Time. To participate in the call from the United States, Canada or an international location, dial (973) 935-2408 and reference call #17144988. The webcast is an audio-only, one-way event. Webcast listeners who wish to ask questions must participate in the conference call. Log onto http://investors.gentiva.com/events.cfm to hear the webcast. A replay of the call will be available on August 1 and will remain available continuously through August 8. To listen to a replay of the call from the United States, Canada or international locations dial (800) 585-8367 or (404) 537-3406 and enter the following PIN at the prompt: 17144988. Visit http://investors.gentiva.com/events.cfm to access the webcast archive. This press release is accessible at http://investors.gentiva.com/releases.cfm and a transcript of the conference call will be posted on the Company's website.

About Gentiva Health Services, Inc.

Gentiva Health Services, Inc. is the nation's largest provider of home health and hospice services based on revenue, delivering innovative, high quality care to patients across the United States. Gentiva is a single source for skilled nursing; physical, occupational, speech and neurorehabilitation services; hospice services; social work; nutrition; disease management education; help with daily living activities; and other therapies and services. GTIV-G

(unaudited tables and notes follow)

Gentiva Health Services, Inc. and Subsidiaries

Condensed Consolidated Financial Statements and Supplemental Information

(Unaudited)


















 

(in 000's, except per share data)

2nd Quarter


Six Months




2013


2012


2013


2012

Condensed Statements of Comprehensive Income (Loss)










Net revenues

$

414,424


$

427,691


$

830,015


$

863,343



Cost of services sold

218,947


222,737


440,520


455,598



Gross profit

195,477


204,954


389,495


407,745



Selling, general and administrative expenses

(161,937)


(163,928)


(321,814)


(337,635)



Gain on sale of businesses


5,447



5,447



Goodwill and other long-lived asset impairment



(224,320)




Interest income

642


697


1,427


1,358



Interest expense and other

(22,790)


(23,352)


(45,868)


(45,515)



Income (loss) before income taxes

11,392


23,818


(201,080)


31,400



Income tax (expense) benefit

(4,829)


(9,646)


587


(12,175)



Net income (loss)

6,563


14,172


(200,493)


19,225



Less: Net income attributable to noncontrolling interests

(216)


(263)


(337)


(476)



Net income (loss) attributable to Gentiva shareholders

$

6,347


$

13,909


$

(200,830)


$

18,749













Total comprehensive income (loss)

$

6,563


$

14,172


$

(200,493)


$

19,225












Earnings per Share










Net income (loss) attributable to Gentiva shareholders:










Basic

$

0.21


$

0.46


$

(6.51)


$

0.61



Diluted

$

0.20


$

0.46


$

(6.51)


$

0.61













Weighted average shares outstanding:










Basic

30,941


30,338


30,863


30,532



Diluted

31,239


30,446


30,863


30,632

 

 

(in 000's)







Condensed Balance Sheets





ASSETS

Jun 30, 2013


Dec 31, 2012



Cash and cash equivalents

$

185,122


$

207,052



Accounts receivable, net (A)

252,589


251,080



Deferred tax assets

9,051


12,263



Prepaid expenses and other current assets

43,162


45,632



Total current assets

489,924


516,027









Notes receivable from CareCentrix

28,471


28,471



Fixed assets, net

38,273


41,414



Intangible assets, net

191,601


193,613



Goodwill

435,747


656,364



Other assets

72,208


75,045



Total assets

$

1,256,224


$

1,510,934








LIABILITIES AND EQUITY






Current portion of long-term debt

$

12,500


$

25,000



Accounts payable

12,706


13,445



Payroll and related taxes

42,069


45,357



Deferred revenue

38,063


37,444



Medicare liabilities

16,035


27,122



Obligations under insurance programs

57,546


56,536



Accrued nursing home costs

19,866


18,428



Other accrued expenses

50,296


66,567



Total current liabilities

249,081


289,899









Long-term debt

897,682


910,182



Deferred tax liabilities, net

31,392


42,165



Other liabilities

39,015


33,988



Total equity

39,054


234,700



Total liabilities and equity

$

1,256,224


$

1,510,934









Common shares outstanding

31,315


30,748







(A) Accounts receivable, net included an allowance for doubtful accounts of $9.1 million and $8.8 million at June 30, 2013 and December 31, 2012, respectively.

 

 

(in 000's)









Six Months

Condensed Statements of Cash Flows

2013


2012


OPERATING ACTIVITIES:





Net (loss) income

$

(200,493)


$

19,225


Adjustments to reconcile net (loss) income to net cash provided
   by operating activities:






Depreciation and amortization

9,511


14,722



Amortization and write-off of debt issuance costs

6,463


7,020



Provision for doubtful accounts

2,680


3,746



Equity-based compensation expense

3,969


3,442



Windfall tax benefits associated with equity-based compensation

(82)




Gain on sale of businesses


(5,447)



Goodwill and other long-lived asset impairment

224,320




Deferred income tax (benefit) expense

(7,983)


9,906


Changes in assets and liabilities, net of effects from acquisitions
   and dispositions:






Accounts receivable

(3,919)


26,251



Prepaid expenses and other current assets

1,727


(7,524)



Current liabilities

(27,705)


(28,314)


Other, net

1,678


6,117


Net cash provided by operating activities

10,166


49,144








INVESTING ACTIVITIES:





Purchase of fixed assets

(7,521)


(6,941)


Proceeds from sale of businesses, net of cash transferred

508


6,090


Net cash used in investing activities

(7,013)


(851)








FINANCING ACTIVITIES:





Proceeds from issuance of common stock

1,852


1,640


Windfall tax benefits associated with equity-based compensation

82



Payment of contingent consideration accrued at acquisition date

(1,500)



Repayment of long-term debt

(25,000)


(50,000)


Repurchase of common stock


(4,974)


Debt issuance costs


(4,125)


Other

(517)


(468)


Net cash used in financing activities

(25,083)


(57,927)








Net change in cash and cash equivalents

(21,930)


(9,634)


Cash and cash equivalents at beginning of period

207,052


164,912


Cash and cash equivalents at end of period

$

185,122


$

155,278








SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:











Interest paid

$

39,069


$

38,402


Income taxes paid

$

522


$

4,014










Six Months

A reconciliation of Free cash flow to Net cash provided by
   operating activities follows:

2013


2012



Net cash provided by operating activities

$

10,166


$

49,144



Less: Purchase of fixed assets

(7,521)


(6,941)



Free cash flow

$

2,645


$

42,203









 

(in 000's)












Supplemental Information

2nd Quarter


Six Months




2013


2012


2013


2012

Segment Information (2)













Net revenues










Home Health

$

235,216


$

235,687


$

471,277


$

475,651



Hospice

179,208


192,004


358,738


387,692


Total net revenues

$

414,424


$

427,691


$

830,015


$

863,343












Operating contribution (4)










Home Health

$

29,917


$

36,383


$

60,105


$

62,259



Hospice

26,437


35,146


53,858


67,628


Total operating contribution

56,354


71,529


113,963


129,887












Corporate administrative expenses

(18,084)


(23,211)


(36,771)


(45,055)


Goodwill and other long-lived asset impairment (5)



(224,320)



Depreciation and amortization

(4,730)


(7,292)


(9,511)


(14,722)


Gain on sale of businesses (6)


5,447



5,447


Interest expense and other, net (7)

(22,148)


(22,655)


(44,441)


(44,157)


Income (loss) before income taxes

$

11,392


$

23,818


$

(201,080)


$

31,400












Home Health operating contribution margin %

12.7%


15.4%


12.8%


13.1%


Hospice operating contribution margin %

14.8%


18.3%


15.0%


17.4%
























2nd Quarter


Six Months


Net Revenues by Major Payer Source:

2013


2012


2013


2012



Medicare










Home Health

$

192,733


$

186,154


$

385,853


$

376,771



Hospice

167,788


179,554


335,061


361,553



Total Medicare

360,521


365,708


720,914


738,324



Medicaid and local government

18,664


18,258


36,934


37,719



Commercial insurance and other:










Paid at episodic rates

13,974


21,313


28,229


41,287



Other

21,265


22,412


43,938


46,013



Total commercial insurance and other

35,239


43,725


72,167


87,300



Total net revenues

$

414,424


$

427,691


$

830,015


$

863,343
























2nd Quarter


Six Months

A reconciliation of Adjusted EBITDA to Net income (loss) attributable to Gentiva shareholders follows:

2013


2012


2013


2012


Adjusted EBITDA (3)

$

39,014


$

48,343


$

78,077


$

90,248


Cost savings, restructuring, legal settlement and acquisition and integration costs (4)

(744)


(25)


(885)


(5,416)


Goodwill and other long-lived asset impairment (5)



(224,320)



Gain on sale of businesses (6)


5,447



5,447


EBITDA (4)

38,270


53,765


(147,128)


90,279


Depreciation and amortization

(4,730)


(7,292)


(9,511)


(14,722)


Interest expense and other, net (7)

(22,148)


(22,655)


(44,441)


(44,157)


Income (loss) before income taxes

11,392


23,818


(201,080)


31,400


Income tax (expense) benefit (8)

(4,829)


(9,646)


587


(12,175)


Net income (loss)

6,563


14,172


(200,493)


19,225


Less: Net income attributable to noncontrolling interests

(216)


(263)


(337)


(476)


Net income (loss) attributable to Gentiva shareholders

$

6,347


$

13,909


$

(200,830)


$

18,749

 


A reconciliation of Adjusted income attributable to Gentiva shareholders to Net income (loss) (all items presented are net of tax): (3)















2nd Quarter


Six Months


2013


2012


2013


2012









Adjusted income attributable to Gentiva shareholders

$

6,799


$

10,695


$

13,906


$

18,140

Cost savings, restructuring, legal settlement and acquisition and integration costs (4)

(452)


(34)


(538)


(3,215)

Goodwill and other long-lived asset impairment (5)



(214,198)


Gain on sale of businesses (6)


3,248



3,248

Tax valuation allowance on OIG legal settlement




576

Income (loss) attributable to Gentiva shareholders

6,347


13,909


(200,830)


18,749

Add back: Net income attributable to noncontrolling interests

216


263


337


476

Net income (loss)

$

6,563


$

14,172


$

(200,493)


$

19,225









Adjusted income attributable to Gentiva shareholders per diluted share

$

0.22


$

0.35


$

0.45


$

0.59

Cost savings, restructuring, legal settlement and acquisition and integration costs (4)

(0.02)



(0.02)


(0.11)

Goodwill and other long-lived asset impairment (5)



(6.94)


Gain on sale of businesses (6)


0.11



0.11

Tax valuation allowance on OIG legal settlement




0.02

Income (loss) attributable to Gentiva shareholders per diluted share

0.20


0.46


(6.51)


0.61

Add back: Net income attributable to noncontrolling interests

0.01


0.01


0.01


0.02

Net income (loss) per diluted share

$

0.21


$

0.47


$

(6.50)


$

0.63

















Operating Metrics

2nd Quarter


Six Months


2013


2012


2013


2012

Home Health








Episodic admissions

48,300


48,800


98,700


100,200

Total episodes

71,000


71,400


143,200


144,800

Episodes per admission

1.47


1.46


1.45


1.44

Revenue per episode

$

2,910


$

2,905


$

2,890


$

2,890









Hospice








Admissions

12,100


12,900


25,700


26,700

Average daily census

12,800


13,700


12,800


13,700

Patient days (in thousands)

1,164


1,243


2,310


2,499

Revenue per patient day

$

154


$

154


$

155


$

155

Length of stay at discharge (in days)

97


86


98


89

Services by patient type:








Routine

98%


98%


98%


98%

General Inpatient & Other

2%


2%


2%


2%

 Notes:

1. The comparability between reporting periods has been affected by the following items:

a. The Company completed several acquisitions, closed a significant number of branch operations and sold a number of operating units affecting the reporting periods presented as follows:

    • During the second quarter of 2013, the Company completed the acquisition of Hope Hospice.
    • During the third quarter of 2012, the Company completed the acquisitions of Family Home Care, North Mississippi Hospice and Advocate Hospice.
    • During the fourth quarter of 2012, the Company sold its Phoenix area hospice operations.  During the second quarter of 2012, the Company sold eight home health branches and four hospice branches in Louisiana.

During the first quarter of 2012, the Company continued a comprehensive review of its branch structure, support infrastructure and other significant expenditures in order to reduce its ongoing operating costs given the challenging rate environment facing the Company. As a result of this effort, the Company closed or divested 4 home health branches and completed significant reductions in staffing levels in regional, area and corporate support functions.

As a result of this activity, the Company's revenue for the second quarter and first six months of 2013 were negatively impacted by approximately $5 million and $14 million, respectively, as compared to the second quarter and first six months of 2012.

b. The first six months of 2013 included 181 days of activity as compared to 182 days for the first six months of 2012 due to 28 days in February 2013 versus 29 days in February 2012.   

2. The Company's senior management evaluates performance and allocates resources based on operating contributions of the operating segments, which exclude corporate expenses, depreciation, amortization, and interest expense and other (net), but include revenues and all other costs directly attributable to the specific segment. 

3. Adjusted EBITDA, a non-GAAP financial measure, is defined as income before interest expense and other (net of interest income), income taxes, depreciation and amortization and excluding charges relating to (i) cost savings and other restructuring, legal settlements, and acquisition and integration activities, (ii) gain on sale of businesses and (iii) goodwill and other long-lived asset impairment.  Management uses Adjusted EBITDA to evaluate overall performance and compare current operating results with other companies in the healthcare industry. Adjusted EBITDA should not be considered in isolation or as a substitute for income from continuing operations, net income, operating income or cash flow statement data determined in accordance with accounting principles generally accepted in the United States.  Because Adjusted EBITDA is not a measure of financial performance under accounting principles generally accepted in the United States and is susceptible to varying calculations, it may not be comparable to similarly titled measures in other companies.

Adjusted income attributable to Gentiva shareholders is defined as income attributable to Gentiva shareholders, excluding (i) tax reserves relating to the OIG settlement, (ii) gain on sale of businesses, (iii) charges relating to cost savings and other restructuring, legal settlements, and acquisition and integration activities and (iv) goodwill and other long-lived asset impairment. 

4. Operating contribution and EBITDA included charges relating to cost savings and other restructuring, legal settlements and acquisition and integration activities of $0.8 million and $0.9 million for the second quarter and first six months of 2013, respectively. For the first six months of 2012, the Company recorded charges of $5.4 million.

For both the second quarter and first six months of 2013, the Company recorded restructuring costs of $0.2 million. For the second quarter and first six months of 2013, acquisition and integration activities of $0.6 million and $0.7 million, respectively, primarily related to the Company's acquisition of Hope Hospice, Inc.

For the first six months of 2012, the Company recorded (i) restructuring costs of $1.3 million and (ii) legal settlement reserves of $5.0 million, associated with the tentative settlement of the Wilkie wage and hour lawsuit, partially offset by a reduction in acquisition and integration costs of $0.9 million, primarily relating to favorable lease settlements associated with Odyssey HealthCare, Inc.

These charges were reflected as follows for segment reporting purposes (dollars in millions):


2nd Quarter


Six Months


2013


2012


2013


2012













Home Health

$


$

(0.1)


$


$

5.7

Hospice

0.7


0.3


0.7


0.1

Corporate expenses

0.1


(0.2)


0.2


(0.4)

Total

$

0.8


$


$

0.9


$

5.4













5. During the first six months of 2013, the Company recorded non-cash charges of $224.3 million related to goodwill and other long-lived assets.

At March 31, 2013, the Company performed an interim impairment test of its Hospice reporting unit due to lower than expected average daily census and higher than expected discharge rates during the quarter. Based on the results of the interim impairment test, the Company's Hospice reporting unit had an estimated fair value of approximately $555 million. As such the Company recorded a non-cash impairment charge relating to goodwill of approximately $220.8 million. As part of that analysis, the Company reviewed the valuation of its owned real estate utilized in the Hospice business. The analysis indicated that two of the Company's hospice inpatient units had estimated fair values lower than their carrying values and, as such, the Company recorded a non-cash impairment charge of approximately $1.9 million.

In addition, the Company conducted an evaluation of the various systems used to support its field operations. In connection with that review, the Company made a strategic decision to replace its business intelligence software platform and, as such, recorded a non-cash impairment charge, related to developed software, of approximately $1.6 million.

6. During the second quarter of 2012, the Company completed the sale of eight home health branches and four hospice branches in Louisiana, pursuant to an asset purchase agreement, for total consideration of approximately $6.4 million

Effective May 31, 2012, the Company completed the sale of its Gentiva consulting business to MP Healthcare Partners, LLC pursuant to an asset purchase agreement, for cash consideration of approximately $0.3 million. In connection with the sales, the Company recorded a gain on sale of businesses of approximately $5.4 million for the second quarter and first six months of 2012.

7. Interest expense and other, net for the first six months of 2012 included charges of approximately $0.5 million relating to the write-off of deferred debt issuance costs associated with Amendment No. 3 to the Company's credit agreement.

8. The Company's effective tax rate was a tax provision of 42.4% and a tax benefit of 0.3% for the second quarter and first six months of 2013, respectively, as compared to a tax provision of 40.5% and 38.8% for the second quarter and first six months of 2012, respectively.

During the first six months of 2013, the Company recorded non-cash impairment charges of $224.3 million related to goodwill and other long-lived assets (see note 5).  Excluding the impact of the impairment charges, the Company's effective tax rate would have been 40.6% for the first six months of 2013.

During the first six months of 2012, the Company recorded a favorable tax reserve adjustment upon resolution of an uncertain tax position associated with the deductibility of a portion of the Company's settlement payment to the Office of the Inspector General.  Excluding the impact of the favorable tax reserve adjustment, the Company's effective tax rate would have been 40.8% for the first six months of 2012.

Forward-Looking Statements

Certain statements contained in this news release, including, without limitation, statements containing the words "believes," "anticipates," "intends," "expects," "assumes," "trends" and similar expressions, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are based upon the Company's current plans, expectations and projections about future events. However, such statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These factors include, among others, the following: economic and business conditions; demographic changes; changes in, or failure to comply with, existing governmental regulations; the impact on our Company of healthcare reform legislation and its implementation through governmental regulations; legislative proposals for healthcare reform; changes in Medicare, Medicaid and commercial payer reimbursement levels; the outcome of any inquiries into the Company's operations and business practices by governmental authorities; compliance with any corporate integrity agreement affecting the Company's operations; effects of competition in the markets in which the Company operates; liability and other claims asserted against the Company; ability to attract and retain qualified personnel; ability to access capital markets; availability and terms of capital; loss of significant contracts or reduction in revenues associated with major payer sources; ability of customers to pay for services; business disruption due to natural disasters, pandemic outbreaks, terrorist acts or cyber-attacks; availability, effectiveness, stability and security of the Company's information technology systems; ability to successfully integrate the operations of acquisitions the Company may make and achieve expected synergies and operational efficiencies within expected time-frames; ability to maintain compliance with its financial covenants under the Company's credit agreement; effect on liquidity of the Company's debt service requirements; and changes in estimates and judgments associated with critical accounting policies and estimates. For a detailed discussion of certain of these and other factors that could cause actual results to differ from those contained in this news release, please refer to the Company's various filings with the Securities and Exchange Commission, including the "Risk Factors" section contained in the Company's annual report on Form 10-K for the year ended December 31, 2012.

Financial and Investor Contact:
Eric Slusser
770-951-6101
eric.slusser@gentiva.com
or
John Mongelli
770-951-6496
john.mongelli@gentiva.com

Media Contact:
Scott Cianciulli
Brainerd Communicators
212-986-6667
cianciulli@braincomm.com

SOURCE Gentiva Health Services, Inc.

News Provided by Acquire Media


Close window | Back to top


Copyright 2014 Gentiva Health Services, Inc.